Business
Theravance Biopharma, Inc. Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Update
- Implied 35% share of YUPELRI® (revefenacin) net sales¹: $15.3M Q4 2021 up 13% from Q4 2020, $56.7M FY 2021 up 13% from FY 2020 - TRELEGY Q4 2021 global net
About this update from Theravance Biopharma, Inc.
[{"type":"text","content":"- Implied 35% share of YUPELRI® (revefenacin) net sales¹: $15.3M Q4 2021 up 13% from Q4 2020, $56.7M FY 2021 up 13% from FY 2020\n - TRELEGY Q4 2021 global net sales: $479M, up 52% from Q4 2020, $1,674M FY 2021² up 58% from FY 2020\n - Continued execution of cost-cutting initiatives; FY'21 R&D OPEX favorable vs. Guidance\n\n\nDUBLIN, Feb. 23, 2022 /PRNewswire/ -- Theravance Biopharma, Inc. (\"Theravance Biopharma\" or the \"Company\") (NASDAQ: TBPH) today reported financial results for the fourth quarter and full year ended December 31, 2021. \n\n \n \n \n \n \n \n\n \n\"While COVID continues to impact communities around the country and health systems are strained, YUPELRI saw the highest quarter of net sales since its launch,\" said Rick E Winningham, Chief Executive Officer. \"I am proud of our team and their ability to find a way to service the COPD community during this challenging time. YUPELRI once a day dosing is proving increasingly important in helping over-burdened healthcare professionals provide relief to their COPD patients. In addition, GSK's TRELEGY sales reached their highest levels since launch driven by growth in the asthma indication.\" \n\"Strong performance by YUPELRI in Q4 and into 2022 will enable us to invest in our inhaled JAK inhibitor respiratory pipeline,\" continued Winningham. \"Through an active business development program, we will continue to unlock value from our non-core asset portfolio throughout 2022. We remain on target to become sustainably cash-flow positive beginning the second half of this year.\"\nYear-end Highlights\nYUPELRI® (revefenacin) inhalation solution, the first and only once-daily, nebulized bronchodilator approved in the US for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD), continued to increase market share and achieved year-over-year net sales growth of 13%; its share of the long-acting nebulized COPD market increased to 23.2% through October 2021 (up from 18.2% in October 2020). On January 10, 2022, the Company announced the enrollment of the first patient in a Phase 4 study of YUPELRI® (read more about the announcement here).Economic Interest \nTRELEGY (first once-daily single inhaler triple therapy for COPD and asthma), in which the Company holds an economic interest, posted fourth quarter 2021 global net sales of $479 million (u...